JR, I., OS, B., M, R., L, A., S, G., E, F., . . . M, D. (2018). Anti-CTLA-4 therapy requires an Fc domain for efficacy. Proceedings of the National Academy of Sciences of the United States of America, 115(15), 3912. https://doi.org/10.1073/pnas.1801524115
Chicago Style (17th ed.) CitationJR, Ingram, et al. "Anti-CTLA-4 Therapy Requires an Fc Domain for Efficacy." Proceedings of the National Academy of Sciences of the United States of America 115, no. 15 (2018): 3912. https://doi.org/10.1073/pnas.1801524115.
MLA (9th ed.) CitationJR, Ingram, et al. "Anti-CTLA-4 Therapy Requires an Fc Domain for Efficacy." Proceedings of the National Academy of Sciences of the United States of America, vol. 115, no. 15, 2018, p. 3912, https://doi.org/10.1073/pnas.1801524115.
Warning: These citations may not always be 100% accurate.
